论文部分内容阅读
目的 随机对照观察肝癌患者术后肝动脉化疗栓塞 (TACE)联合胸腺肽α1(Tα1)治疗对预防肝细胞癌复发的影响。方法 5 7例肝细胞癌患者随机分为 3组 :手术 +TACE +Tα1组 (A组 ) 18例 ,手术 +TACE组 (B组 ) 2 3例和手术切除组 (C组 ) 16例。观察患者术后肿瘤复发率、复发时间和生存期。结果 A、B、C组 1年复发率分别为 83.3%、87.0 %和 87.5 % (P =0 .92 6 ) ,中位复发时间分别为7.0个月、5 .0个月和 4 .0个月 (P =0 .0 39) ,中位生存期分别为 10 .0个月、7.0个月和 8.0个月 (P =0 .0 0 2 )。结论 术后TACE +Tα1治疗不能降低肝细胞癌患者术后复发率 ,但可延缓复发时间 ,提高生存期。
Objective To observe the effect of postoperative transcatheter arterial chemoembolization (TACE) combined with thymosin α1 (Tα1) on the prevention of recurrence of hepatocellular carcinoma in patients with hepatocellular carcinoma (HCC). Methods Totally 57 hepatocellular carcinoma patients were randomly divided into 3 groups: operation + TACE + Tα1 group (A group), surgery + TACE group (B group) and surgical resection group (C group). Postoperative tumor recurrence rate, recurrence time and survival were observed. Results The 1-year recurrence rates in groups A, B and C were 83.3%, 87.0% and 87.5%, respectively (P = 0.92 6). The median recurrence time was 7.0 months, 5.0 months and 4.0 months Month (P = 0.039). The median survival time was 10.0 months, 7.0 months and 8.0 months respectively (P = 0.002). Conclusion TACE + Tα1 treatment can not reduce the recurrence rate of patients with hepatocellular carcinoma, but can delay the recurrence time and improve the survival time.